Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• 主要な著者: Xiaomin Wan (著者), Xiaohui Zeng (著者), Liubao Peng (著者), Ye Peng (著者), Qiao Liu (著者), Lidan Yi (著者), Xia Luo (著者), Qijian Deng (著者), Chongqing Tan (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...